Global Macugen Price 2025, Forecast To 2034
11 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Macugen Market?
The macugen market has seen considerable growth due to a variety of factors.
• Recent years have seen the Macugen market size expand at a rate of XX (HCAGR). A growth from $XX million in 2024 to an expected $XX million in 2025, equates to a compound annual growth rate (CAGR) of XX%.
Factors contributing to this significant growth during the historical period include the escalating elderly population, an increase in patient consciousness about health, an expansion in healthcare expenditure, a rise in research and development activities, and the burgeoning number of emerging markets.
What is the Forecasted Market Size and CAGR for the Macugen Market?
The macugen market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of Macugen is anticipated to witness a forward compound annual growth rate (FCAGR) of XX in the coming years and is projected to escalate to $XX million by 2029 with a compound annual growth rate (CAGR) of XX%.
The expected growth in the forecast period can be ascribed to a surge in diagnostic and treatment rates, an increased occurrence of wet AMD, a rising presence of AMD, augmented investments in healthcare facilities, and increased awareness of diabetic eye disorders. The upcoming trends within the forecast period encompass a move towards mixed treatments, enhancements in drug delivery mechanisms, technological breakthroughs in the field of ophthalmology, progress in diagnostic methods, and the emergence of advanced therapies for AMD.
What Key Factors and Trends Are Driving The Growth Macugen Market?
The anticipated surge in Age-related macular degeneration (AMD) cases is projected to catalyze an expansion in the macugen market. Age-related macular degeneration (AMD) is an advancing eye disorder affecting the macula, which is the central section of the retina that facilitates clear, detailed vision. The surge in AMD cases is tied to a globally aging population, extended life spans, and lifestyle components such as smoking, unhealthy diets, and prolonged exposure to ultraviolet (UV) light. Macugen is advantageous in AMD treatment as it inhibits vascular endothelial growth factor (VEGF), curtails abnormal blood vessel growth and leakage in the retina, thus aiding in vision preservation and decelerating disease advancement. For example, an article by the National Center for Biotechnology Information, a US-based National Institutes of Health government agency, in May 2023 forecasts that around 288 million individuals will be affected by AMD in 2040. Consequently, the escalating prevalence of AMD is propelling the expansion of the macugen market.
What Are The Market Segments In The Macugen Market?
The macugen market covered in this report is segmented –
1) By Indication: Wet AMD(Age-Related Macular Degeneration (AMD)), Diabetic Macular Edema
2) By Formulation: Intravitreal Injection, Extended-Release Formulations
3) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies
4) By End User: Adult Patients, Geriatric Patients
What Trends Are Shaping The Macugen Market?
Gene therapy represents a major movement in the Macugen market, an innovative approach where genetic material is delivered into a patient's cells to treat or prevent disease, specifically focusing on age-related macular degeneration (AMD). For instance, Regenxbio, a biotech firm headquartered in the US, introduced RGX-314 in 2023. It's a product for gene therapy that has been designed to transmit a gene encoding for an anti-VEGF protein directly into the eye. This groundbreaking treatment is aimed at offering enduring effects by minimizing the necessity for routine injections. RGX-314 stands out due to its possibilities of a single administration, which can considerably enhance patient adherence, and its capacity to address the root issues of AMD instead of just controlling symptoms. Such advancements position corporations well within the dynamic field of ocular therapies.
Who Are the Key Players In The Macugen Market?
Major companies operating in the macugen market are:
• Bausch + Lomb Inc
What Are The Regional Insights Into The Macugen Market?
North America was the largest region in the macugen market in 2024. The regions covered in the macugen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.